A Phase 3 interventional study of Oral treprostinil (UT-15C) sustained release tablets and Placebo in Pulmonary Hypertension, sponsored by United Therapeutics. Completed at 72 sites in 14 countries. Open to participants aged 12 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-08-02.
Sponsored by United Therapeutics · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 4th largest by enrollment, is one of 2 that started in 2006, is one of 14 in phase 3, and was the 3rd registered.
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
Browse Pulmonary Arterial Hypertension studies →3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:
Liquidia Technologies, Inc. · Sites in United States
Ages 18–80
University of Arizona · Sites in United States
Ages 18+
Shanghai Zhongshan Hospital
Ages 18–75
By country, each count listing its studies:
treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →
Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.
This study: 12 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
44 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2006.
This study's enrollment of 354 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Median enrollment 32 across the 44 interventional studies. Of the 32 that completed or were terminated, 20 (63%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 44 have an industry lead sponsor. The 10 most frequent:
United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
51 studies in Pulmonary Arterial Hypertension by United Therapeutics: 1 open now, 3 under way, 1 of them phase 3. Of 40 finished, 28 (70%) have results posted.
Among the 51 studies in Pulmonary Arterial Hypertension by United Therapeutics, this one is the 6th largest by enrollment of the 45 interventional ones that give a count, is one of 2 that started in 2006, is one of 17 in phase 3, and was the 3rd registered.
United Therapeutics’s Pulmonary Arterial Hypertension studies by the year they started, since 2002.
1 of the studies testing treprostinil in Pulmonary Arterial Hypertension that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759804Liquidia Technologies, Inc.A Study of Inhaled Treprostinil (LIQ861) in Adults With Pulmonary Arterial Hypertension Transitioning From Oral Selexipag | 2027-05 |
Add it to your calendar (.ics) → With an account.
Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, from their registry updates:
Among United Therapeutics’s 51 in Pulmonary Arterial Hypertension:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This study was an international, multi-center, randomized, double-blind, placebo-controlled study in subjects with PAH who were currently receiving approved therapy for their PAH (i.e., endothelin receptor antagonist and/or phosphodiesterase-5 inhibitor). Study visits occurred at 4 week intervals for 16 weeks; the key measure of efficacy was the 6-minute walk test. Study procedures included routine blood tests, medical history, physical exams, disease evaluation, and exercise tests. One optional substudy was also a part of FREEDOM-C at select centers - a hemodynamic substudy with a right heart catheterization at Baseline and Week 16.
Patients who completed all assessments for 16-weeks were also eligible to enter an open-label, extension phase study (FREEDOM - EXT).
701 studies on the registry are indexed under Pulmonary Arterial Hypertension; 142 are open to participants now.
This study's enrollment of 354 is above the median of 40 across 478 interventional studies indexed under Pulmonary Arterial Hypertension.
Browse Pulmonary Arterial Hypertension studies →United Therapeutics is the lead sponsor of 85 studies on the registry; 8 are open to participants now.
Of its 17 completed or terminated interventional studies of FDA-regulated products, 15 (88%) have results posted.
Compared within Pulmonary Arterial Hypertension, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Hypertension, Pulmonary. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects assigned to active therapy with UT-15C 0.25, 0.5, 1, or 5 mg oral tablets.
Drug: Oral treprostinil (UT-15C) sustained release tablets
Subjects assigned to placebo 0.25, 0.5, 1, or 5 mg oral tablets.
Drug: Placebo
UT-15C 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
Placebo 0.25, 0.5, 1, or 5 mg oral tablets by mouth every 12 hours
Six Minute Walk Distance (6MWD)
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 16, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.
Time frame: Baseline and 16 Weeks
Borg Dyspnea Score
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).
Time frame: Baseline and 16 Weeks
Clinical Worsening Assessment
Definition of clinical worsening required one of the following: 1. Death (all causes excluding accident) 2. Transplantation or atrial septostomy 3. Clinical deterioration as defined by: 1. Hospitalization as a result of PAH, or 2. ≥ 20% decrease in 6-minute walk distance from Baseline (or too ill to walk) and a decrease in WHO functional class And 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5I, prostacyclin).
Time frame: Baseline and 16 Weeks
Dyspnea-Fatigue Index
The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.
Time frame: Baseline and 16 Weeks
World Health Organization Functional Classification for PAH
Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.
Time frame: Week 16
Six Minute Walk Distance (6MWD)
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.
Time frame: Baseline and 12 weeks
Six Minute Walk Distance (6MWD)
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.
Time frame: Baseline and 8 weeks
Six Minute Walk Distance (6MWD)
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.
Time frame: Baseline and 4 weeks
Change in Symptoms of PAH From Baseline to Week 16
Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 16. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom. The outcome data describes the change in severity values from Baseline to Week 16 for each defined symptom of PAH.
Time frame: Baseline and 16 weeks
354 subjects were randomized with 350 subjects receiving a dose of study drug and subsequently analyzed from 20 October 2006 to 17 September 2008 at 70 sites across the United States, Canada, Europe, Israel, and Australia.
| Milestone | Placebo Arm | Active |
|---|---|---|
| Started | 176 | 174 |
| Completed | 167 | 153 |
| Not completed | 9 | 21 |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 16, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 362.5 (302.0 to 400.0) | 362.5 (304.0 to 397.0) |
| 6MWD at Week 16 | 367.0 (283.0 to 420.5) | 381.0 (323.0 to 420.0) |
| Change in 6MWD from Baseline to Week 16 | 4.8 (-22.0 to 35.5) | 14.5 (-10.0 to 47.0) |
The Borg dyspnea score is a 10-point scale rating the maximum level of dyspnea experienced during the 6-minute walk test. The Borg dyspnea score was assessed immediately following the 6-minute walk test. Scores ranged from 0 (for no shortness of breath) to 10 (for greatest shortness of breath ever experienced).
| units on a scale | Placebo Arm | Active |
|---|---|---|
| Borg dyspnea score at Baseline | 4.26 ± 2.25 | 4.22 ± 2.24 |
| Borg dyspnea score at Week 16 | 4.64 ± 2.62 | 4.18 ± 2.59 |
| Change in Borg dyspnea score from BL to Wk 16 | 0.38 ± 2.06 | -0.03 ± 2.13 |
Definition of clinical worsening required one of the following: 1. Death (all causes excluding accident) 2. Transplantation or atrial septostomy 3. Clinical deterioration as defined by: 1. Hospitalization as a result of PAH, or 2. ≥ 20% decrease in 6-minute walk distance from Baseline (or too ill to walk) and a decrease in WHO functional class And 3. Initiation of new PAH specific therapy (i.e., ERA, PDE5I, prostacyclin).
| participants | Placebo Arm | Active |
|---|---|---|
| Clinical Worsening Assessment | 12 | 8 |
The dyspnea-fatigue index has three components, each rated on a scale of 0 to 4, for the magnitude of the task that evokes dyspnea or fatigue, the magnitude of the pace (or effort) with which the task is performed and the associated functional impairment in general activities. The ratings for each component were added to form an aggregate score, which could range from 0, for the worst condition, to 12, for the best.
| units on a scale | Placebo Arm | Active |
|---|---|---|
| Dyspnea-fatigue index at Baseline | 5.5 ± 2.2 | 5.7 ± 2.1 |
| Dyspnea-fatigue index at Week 16 | 5.1 ± 2.5 | 5.7 ± 2.5 |
| Change in dyspnea-fatigue index from BL to Wk 16 | -0.4 ± 1.9 | 0.0 ± 1.9 |
Class I: Patients with pulmonary hypertension but without resulting limitation of physical activity. Ordinary physical activity does not cause undue dyspnea or fatigue, chest pain, or near syncope. Class II: Patients with pulmonary hypertension resulting in slight limitation of physical activity. These patients are comfortable at rest, but ordinary physical activity causes undue dyspnea or fatigue, chest pain or near syncope. Class III: Patients with pulmonary hypertension resulting in marked limitation of physical activity. They are comfortable at rest. Ordinary activity causes undue dyspnea or fatigue, chest pain, or near syncope. Class IV: Patients with pulmonary hypertension with inability to carry out any physical activity without symptoms. These patients manifest signs of right heart failure. Dyspnea and/or fatigue may be present even at rest. Discomfort is increased by any physical activity.
| participants | Placebo Arm | Active |
|---|---|---|
| WHO Class I | 1 | 2 |
| WHO Class II | 48 | 58 |
| WHO Class III | 114 | 103 |
| WHO Class IV | 13 | 11 |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 12, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 362.5 (302.0 to 400.0) | 362.5 (304.0 to 397.0) |
| 6MWD at Week 12 | 366.4 (280.5 to 424.0) | 378.0 (320.0 to 425.0) |
| Change in 6MWD from Baseline to Week 12 | 5.8 (-23.5 to 29.5) | 16.5 (-15.0 to 51.0) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 8, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 362.5 (302.0 to 400.0) | 362.5 (304.0 to 397.0) |
| 6MWD at Week 8 | 368.5 (294.5 to 416.0) | 379.0 (310.0 to 415.0) |
| Change in 6MWD from Baseline to Week 8 | 7.0 (-22.0 to 30.5) | 15.0 (-9.0 to 42.0) |
Placebo corrected change in six minute walk distance (6MWD) from Baseline to Week 4, correlates with the historical clinical standard for assessing patient functional status in the treatment of PAH and is considered an objective measure of patient functional status by the American Thoracic Society (ATS). The six minute walk test was to be conducted 3 to 6 hours after the previous dose of study drug.
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 362.5 (302.0 to 400.0) | 362.5 (304.0 to 397.0) |
| 6MWD at Week 4 | 363.0 (299.0 to 410.5) | 370.5 (312.0 to 410) |
| Change in 6MWD from Baseline to Week 4 | 2.1 (-17.5 to 24.5) | 5.5 (-8.0 to 31.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 247.0 (191.0 to 288.0) | 255.0 (204.0 to 289.0) |
| 6MWD at Week 16 | 241.0 (141.0 to 286.0) | 265.0 (189.0 to 325.0) |
| Change in 6MWD from Baseline to Week 16 | -5.6 (-39.0 to 16.0) | 17.0 (-13.0 to 43.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 332.0 (323.0 to 354.0) | 339.0 (323.5 to 350.5) |
| 6MWD at Week 16 | 348.0 (300.0 to 376.0) | 359.0 (329.5 to 400.5) |
| Change in 6MWD from Baseline to Week 16 | 12.0 (-22.0 to 37.0) | 17.0 (-0.4 to 53.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 385.0 (378.0 to 390.0) | 383.0 (376.0 to 390.0) |
| 6MWD at Week 16 | 388.0 (358.0 to 429.0) | 396.0 (370.0 to 417.0) |
| Change in 6MWD from Baseline to Week 16 | 6.5 (-22.0 to 43.0) | 13.0 (-8.0 to 44.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 425.5 (410.0 to 440.0) | 425.0 (412.0 to 430.0) |
| 6MWD at Week 16 | 442.0 (411.0 to 468.0) | 438.5 (395.0 to 483.0) |
| Change in 6MWD from Baseline to Week 16 | 15.0 (-6.0 to 49.0) | 15.0 (-20.0 to 59.0) |
In general, the dose of study drug was increased in 0.5 mg increments every 3 days, in the absence of dose-limiting drug-related AEs, to ensure the subject received the optimal clinical dose throughout the study.
| meters | Less Than 1 mg or Discontinuation Due to Adverse Events | 1.25 - 3.25 mg | 3.5 - 16 mg |
|---|---|---|---|
| Change in Six Minute Walk Distance (6MWD) From Baseline in Subjects Who Received Oral Treprostinil by Last Study Drug Dose and Reason for Discontinuation | 3.8 (-8.0 to 26.0) | 18.0 (-3.0 to 56.0) | 34.0 (3.0 to 52.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 348.0 (282.0 to 385.0) | 349.0 (311.0 to 380.0) |
| 6MWD at Week 16 | 350.0 (243.0 to 431.0) | 379.0 (324.7 to 405.0) |
| Change in 6MWD from Baseline to Week 16 | 15.0 (-26.0 to 55.0) | 22.0 (5.0 to 45.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 366.0 (302.0 to 410.0) | 370.0 (297.0 to 411.0) |
| 6MWD at Week 16 | 370.0 (283.0 to 430.0) | 375.5 (301.0 to 439.5) |
| Change in 6MWD from Baseline to Week 16 | 7.0 (-19.0 to 30.0) | 7.0 (-19.0 to 46.5) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 374.0 (319.0 to 408.0) | 384.0 (306.0 to 405.0) |
| 6MWD at Week 16 | 374.0 (320.0 to 399.0) | 398.0 (340.0 to 438.0) |
| Change in 6MWD from Baseline to Week 16 | -1.0 (-30.0 to 12.0) | 21.0 (-7.0 to 78.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 382.0 (325.0 to 403.0) | 372.0 (325.0 to 398.0) |
| 6MWD at Week 16 | 377.0 (303.0 to 423.0) | 385.0 (306.4 to 422.0) |
| Change in 6MWD from Baseline to Week 16 | -3.0 (-22.0 to 30.0) | 4.0 (-16.0 to 40.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 360.0 (302.0 to 397.0) | 348.0 (296.0 to 390.0) |
| 6MWD at Week 16 | 357.0 (318.0 to 424.0) | 373.0 (307.0 to 411.0) |
| Change in 6MWD from Baseline to Week 16 | 8.0 (-31.0 to 47.0) | 23.0 (-3.0 to 47.0) |
| meters | Placebo Arm | Active |
|---|---|---|
| 6MWD at Baseline | 351.5 (290.0 to 400.0) | 358.5 (300.0 to 412.0) |
| 6MWD at Week 16 | 359.2 (243.0 to 418.0) | 381.0 (325.0 to 425.0) |
| Change in 6MWD from Baseline to Week 16 | 8.0 (-20.0 to 35.0) | 14.5 (-13.0 to 47.0) |
Defined symptoms of PAH including fatigue, dyspnea, edema, dizziness, syncope, chest pain, and orthopnea were assessed at Baseline prior to starting study drug and during the Treatment Phase at Week 16. Severity grade values (i.e., 0, 1, 2, or 3 in increasing severity) were assigned for each symptom. The outcome data describes the change in severity values from Baseline to Week 16 for each defined symptom of PAH.
| units on a scale | Placebo Arm | Active |
|---|---|---|
| Change in fatigue symptoms | 0.0 ± 0.0 | 0.01 ± 0.10 |
| Change in dypsnea symptoms | 0.00 ± 0.00 | -0.01 ± 0.09 |
| Change in edema symptoms | 0.00 ± 0.00 | -0.06 ± 0.10 |
| Change in dizziness symptoms | 0.00 ± 0.00 | -0.16 ± 0.11 |
| Change in syncope symptoms | 0.00 ± 0.00 | -0.10 ± 0.09 |
| Change in chest pain symptoms | 0.00 ± 0.00 | -0.09 ± 0.11 |
| Change in orthopnea symptoms | 0.00 ± 0.00 | -0.20 ± 0.10 |
Collected over Adverse events were recorded throughout the 16 week study which was conducted between October 2006 and September 2008.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo Arm | — | 33/176 (18.8%) | 157/176 (89.2%) |
| Active | — | 32/174 (18.4%) | 173/174 (99.4%) |
| Event | Placebo Arm | Active |
|---|---|---|
| Pulmonary arterial hypertensionRespiratory, thoracic and mediastinal disorders | 8/176 | 9/174 |
| right ventricular failureCardiac disorders | 2/176 | 6/174 |
| renal failure acuteRenal and urinary disorders | 0/176 | 3/174 |
| syncopeGeneral disorders | 3/176 | 2/174 |
| dyspneaRespiratory, thoracic and mediastinal disorders | 3/176 | 1/174 |
| atrial flutterCardiac disorders | 1/176 | 2/174 |
| chest painCardiac disorders | 2/176 | 0/174 |
| hypotensionVascular disorders | 2/176 | 0/174 |
| nauseaGastrointestinal disorders | 2/176 | 0/174 |
| pneumoniaRespiratory, thoracic and mediastinal disorders | 2/176 | 0/174 |
| Event | Placebo Arm | Active |
|---|---|---|
| headacheNervous system disorders | 65/176 | 150/174 |
| nauseaGastrointestinal disorders | 60/176 | 112/174 |
| diarrheaGastrointestinal disorders | 48/176 | 106/174 |
| flushingVascular disorders | 27/176 | 85/174 |
| vomitingGastrointestinal disorders | 14/176 | 76/174 |
| pain in jawMusculoskeletal and connective tissue disorders | 21/176 | 75/174 |
| pain in extremityMusculoskeletal and connective tissue disorders | 17/176 | 54/174 |
| dizzinessEar and labyrinth disorders | 28/176 | 30/174 |
| fatigueGeneral disorders | 17/176 | 25/174 |
| myalgiaMusculoskeletal and connective tissue disorders | 6/176 | 24/174 |
| Age, Categorical(Participants) | Placebo Arm | Active | Total |
|---|---|---|---|
| <=18 years | 5 | 3 | 8 |
| Between 18 and 65 years | 149 | 151 | 300 |
| >=65 years | 22 | 20 | 42 |
| Age, Continuous(years) | Placebo Arm | Active | Total |
|---|---|---|---|
| Mean | 49.5 ± 13.3 | 51.1 ± 12.3 | 50.3 ± 12.8 |
| Sex: Female, Male(Participants) | Placebo Arm | Active | Total |
|---|---|---|---|
| Female | 140 | 148 | 288 |
| Male | 36 | 26 | 62 |
| Distance Traversed (meters) During Six Minute Walk Test at Baseline(meters) | Placebo Arm | Active | Total |
|---|---|---|---|
| Mean | 345.4 ± 75.5 | 346.1 ± 71.4 | 345.7 ± 73.4 |
| Baseline WHO Functional Classification(participants) | Placebo Arm | Active | Total |
|---|---|---|---|
| WHO Functional Class I | 1 | 2 | 3 |
| WHO Functional Class II | 31 | 41 | 72 |
| WHO Functional Class III | 139 | 127 | 266 |
| WHO Functional Class IV | 5 | 4 | 9 |
| PAH Etiology(participants) | Placebo Arm | Active | Total |
|---|---|---|---|
| Idiopathic / familial PAH | 119 | 113 | 232 |
| PAH associated with collagen vasular disease | 43 | 49 | 92 |
| PAH associated wtih congenital heart defect | 11 | 11 | 22 |
| PAH associated with HIV infection | 3 | 1 | 4 |
| Background PAH Therapy(participants) | Placebo Arm | Active | Total |
|---|---|---|---|
| ERA | 51 | 55 | 106 |
| PDE5-I | 43 | 45 | 88 |
| ERA and PDE5-I | 82 | 74 | 156 |
The record gives a start of Oct 2006, a primary completion of Sep 2008 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2013, 4 years 9 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Treprostinil
Pulmonary Arterial Hypertension →